Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.

Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR.

Am J Hematol. 2012 Sep;87(9):880-5. doi: 10.1002/ajh.23273. Epub 2012 Jun 20.

PMID:
22718493
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.

Hu W, Bassig BA, Xu J, Zheng T, Zhang Y, Berndt SI, Holford TR, Hosgood HD 3rd, Leaderer B, Yeager M, Menashe I, Boyle P, Zou K, Zhu Y, Chanock S, Lan Q, Rothman N.

Environ Mol Mutagen. 2013 Jan;54(1):72-7. doi: 10.1002/em.21739. Epub 2012 Oct 11.

PMID:
23055202
[PubMed - indexed for MEDLINE]
3.

The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.

Watanabe R, Tomita N, Matsumoto C, Hattori Y, Matsuura S, Takasaki H, Hashimoto C, Fujita H, Fujisawa S, Ishigatsubo Y.

J Clin Exp Hematop. 2013;53(2):107-14.

PMID:
23995106
[PubMed - indexed for MEDLINE]
Free Article
4.

Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.

Dzietczenia J, Wróbel T, Mazur G, Poreba R, Jaźwiec B, Kuliczkowski K.

Med Oncol. 2010 Sep;27(3):743-6. doi: 10.1007/s12032-009-9278-9. Epub 2009 Aug 7.

PMID:
19662541
[PubMed - indexed for MEDLINE]
5.

Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, Syrbu SI, Kurtin PJ, Macon WR, Nikcevich DA, Witzig TE.

J Clin Oncol. 2011 Apr 20;29(12):1620-6. doi: 10.1200/JCO.2010.29.4413. Epub 2011 Mar 7.

PMID:
21383282
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.

Keegan TH, Moy LM, Foran JM, Alizadeh AA, Chang ET, Shema SJ, Schupp CW, Clarke CA, Glaser SL.

Leuk Lymphoma. 2013 Apr;54(4):743-51. doi: 10.3109/10428194.2012.727415. Epub 2012 Sep 28.

PMID:
22957852
[PubMed - indexed for MEDLINE]
7.

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.

Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Cook JR, Tubbs RR, Gascoyne RD, Armitage JO, Weisenburger DD, Chan WC.

Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.

PMID:
21933893
[PubMed - indexed for MEDLINE]
Free Article
8.

Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.

Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock SJ, Cerhan JR.

Blood. 2008 Oct 1;112(7):2694-702. doi: 10.1182/blood-2007-09-111658. Epub 2008 Jul 16.

PMID:
18633131
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Risk of non-Hodgkin lymphoma in association with germline variation in complement genes.

Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, Dogan A, Witzig TE, Ansell SM, Habermann TM, Kay NE, Slager SL.

Br J Haematol. 2009 Jun;145(5):614-23. doi: 10.1111/j.1365-2141.2009.07675.x. Epub 2009 Mar 30.

PMID:
19344414
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.

Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ.

Cytokine. 2012 Dec;60(3):882-9. doi: 10.1016/j.cyto.2012.08.028. Epub 2012 Sep 23.

PMID:
23010502
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.

Rossi D, Rasi S, Franceschetti S, Capello D, Castelli A, De Paoli L, Ramponi A, Chiappella A, Pogliani EM, Vitolo U, Kwee I, Bertoni F, Conconi A, Gaidano G.

Leukemia. 2009 Jun;23(6):1118-26. doi: 10.1038/leu.2008.398. Epub 2009 Jan 29.

PMID:
19448608
[PubMed - indexed for MEDLINE]
12.

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.

Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ.

Clin Cancer Res. 2008 Oct 15;14(20):6697-703. doi: 10.1158/1078-0432.CCR-08-0745.

PMID:
18927313
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.

Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS, Chanock SJ, Rothman N, Hartge P, Dogan A, Wang SS.

Leuk Lymphoma. 2012 Jun;53(6):1105-12. doi: 10.3109/10428194.2011.638717. Epub 2012 Jan 3.

PMID:
22066713
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.

Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J.

Blood. 2011 Oct 27;118(17):4657-62. doi: 10.1182/blood-2011-04-346411. Epub 2011 Sep 7.

PMID:
21900198
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N.

J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.

PMID:
20660832
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.

Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G.

Blood. 2012 Sep 27;120(13):2650-7. Epub 2012 Aug 10.

PMID:
22885164
[PubMed - indexed for MEDLINE]
Free Article
17.

Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.

Nagai H, Yano T, Watanabe T, Uike N, Okamura S, Hanada S, Kawano F, Sunami K, Inoue N, Sawamura M, Nishiura T, Hotta T, Horibe K.

Br J Haematol. 2008 Dec;143(5):672-80. doi: 10.1111/j.1365-2141.2008.07390.x. Epub 2008 Oct 20.

PMID:
18950459
[PubMed - indexed for MEDLINE]
18.

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ.

Am J Hematol. 2012 Sep;87(9):865-9. doi: 10.1002/ajh.23259. Epub 2012 Jun 3.

PMID:
22674570
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma.

Tada K, Kim SW, Asakura Y, Hiramoto N, Yakushijin K, Kurosawa S, Tajima K, Mori S, Heike Y, Tanosaki R, Maeshima AM, Taniguchi H, Furuta K, Kagami Y, Matsuno Y, Tobinai K, Takaue Y, Fukuda T.

Am J Hematol. 2012 Aug;87(8):770-5. doi: 10.1002/ajh.23246. Epub 2012 May 28.

PMID:
22641292
[PubMed - indexed for MEDLINE]
20.

Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.

Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, Lee DH, Kim SW, Lee JS, Suh C.

Korean J Intern Med. 2010 Sep;25(3):301-8. doi: 10.3904/kjim.2010.25.3.301. Epub 2010 Aug 31.

PMID:
20830228
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk